WHY IS ASIABIO BUYING ONLY NETX AND NOT DGB, MLAB, XOX, VSOLAR FINTEC & OTHERS? Calvin Tan Research

October 26, 2019 By Calvin Tan Smart Investment

Dear Friends, Investors & Traders,

Why is Asiabio Directors buying Netx and not Fintec, Mlab, XOX, DGB, VSolar or other shares in which they are also have  Directorships in?

See

NETX

AS YOU CAN SEE CLEARLY ASIABIO HAS BOUGHT A TOTAL OF 130 MILLIONS NETX SHARES IN THE OPEN MARKET WITH PRICES RANGING FROM 1.5 SEN TO 2 SEN

ALTHOUGH THE DIRECTORS OF NETX DO NOT OWN NETX SHARES DIRECTLY THEY INVESTED IN NETX THROUGH THEIR HOLDING OF ASIABIO SHARES OR ALSO CALLED FINTEC

SEE

FINTEC/ASIABIO

IF YOU CHECK UP THE MISSION STATEMENT OF ASIABIO YOU WILL NOTICE THAT ASIABIO/FINTEC IS AN INCUBATOR COMPANY LIKE OSKVi ONCE DID

OSKVI FOUNDED & INCUBATED 2 SUCCESSFUL COMPANIES CALLED GREEN PACKET & MTOUCHE. ALTHOUGH OSKVi MADE THE MISTAKE OF SELLING OUT GPACKET TOO EARLY  AT A LOSS AFTER MANY TRYING YEARS. BUT GPACKET IS NOW A SUCCESS

SO IS ASIABIO/FINTEC. AMONG THE COMPANIES ASIABIO TOOK UP POSITION ARE NETX, FOCUS DYNAMIC, VSOLAR, XOX, DGB, MLAB & OTHERS

AND ASIABIO HAS BEEN DOING AN EXCELLENT JOB IN ITS INVESTMENT SO FAR

SEE ITS BALANCE SHEET

SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2019
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30 Jun 2019
30 Jun 2018
30 Jun 2019
30 Jun 2018
$$’000
$$’000
$$’000
$$’000
1 Revenue
9,689
437
9,689
437
2 Profit/(loss) before tax
24,469
-31,565
24,469
-31,565
3 Profit/(loss) for the period
24,469
-31,565
24,469
-31,565
4 Profit/(loss) attributable to ordinary equity holders of the parent
24,471
-31,561
24,471
-31,561
5 Basic earnings/(loss) per share (Subunit)
4.00
-5.53
4.00
-5.53
6 Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00
AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7 Net assets per share attributable to ordinary equity holders of the parent ($$)
0.2869
0.3525

See the 4 sen profit made by Asiabio/Fintec

Let’s take a deeper look by visiting its balance sheet

The Group’s revenue for the period ending 30 June 2019 was RM9.69 million, an increase of RM9.25 million or 2.12x as compared to RM0.44 million in the previous year’s corresponding period. The increase in revenue for the quarter was

mainly due to the sale of short term marketable securities.

The Group made a profit before tax of RM24.47 million for the period ending 30 June 2019 as opposed to loss before tax of RM31.57 million in the corresponding period ending 30 June 2018 and the net loss attributable to equity holders was RM24.47 million, an increase of profit of RM56.03 million or 1.78x as compared to the net loss attributable to equity holders of RM31.56 million in previous year’s corresponding period. The increase of profit was mainly due to mark-to-market gain in the Group’s long term marketable securities.

The Group’s investment in marketable securities increased by RM19.74 million or 18.9% to RM124.27 million as at 30 June 2019 as compared to RM104.53 million as at 30 June 2018, which was mainly due to fair value gain on quoted securities

FROM THE ABOVE WE CAN CLEARLY SEE THAT ASIABIO/FINTEC ACTUALLY MADE ITS PROFITS FROM

The increase of profit was mainly due to mark-to-market gain in the Group’s long term marketable securities.

IN OTHER WORDS ASIABIO MADE MONIES FROM SHARE INVESTMENTS!!!

THIS LATEST QUARTER REPORT OF ASIABIO WAS FOR APRIL, MAY & JUNE MONTH OF SUCCESSFUL INVESTMENT IN QUOTED SHARES

FROM WHAT SHARES?

GO SEE FOCUS DYNAMIC SHARE PRICE

FOCUS DYNAMICS GROUP BERHAD (0116)

Company Website
Annual Report
General Meetings

FOCUS DYNAMICS GROUP BERHAD (0116) Chart

Chart Period:

CLICK ON ONE (1) YEAR CHART

SEE HOW ASIOBIO DIRECTORS MADE A CHUN CHUN BUY ON FOCUS AT 13.5 SEN. AND FOCUS UP  177% TO REACH 37.5 SEN (Please don’t chase Focus now)

SEE HOW & WHEN  ASIABIO BOUGHT

ON JUNE 13TH 2018 ASIABIO BOUGHT FOCUS SHARES FROM OPEN MARKET AT ONLY 13.5 SEN

FOCUS DYNAMIC AT CURRENT PRICE OF 37.5 SEN MEANS IT HAS GAINED 177% ALREADY

NOT BAD AT ALL IN JUST ONE YEAR 4 MONTHS

NOW YOU MUST KNOW ASIABIO BOUGHT 103 MILLIONS NETX SHARES FROM AUGUST 6 TO 23 2019 AS HIGH AS 2 SEN

SHOULD NETX ALSO PERFORM LIKE FOCUS DYNAMIC AT 177% RISE THEN IT WILL BE 5.54 SEN PER SHARE FOR NETX

SURPRISINGLY, ASIABIO DID NOT SELL ITS FOCUS SHARES. SO WILL ASIABIO BE STILL HOLDING NETX SHARES WHEN NETX ALSO EVENTUALLY CROSS 5 SEN?

I THINK SO

WITH NOTHING TO PUSH FOCUS IT CAN STILL GO UP 177% NOW WITH RM21.6 BILLIONS PUSHING NETX CALVIN THINKS IT COULD EASILY MOVE UP TO OUR TARGET PRICE OF 8 SEN EASILY

THINK AHEAD WITH ME NOW

TODAY, ONLY CALVIN IS CALLING FOR A BUY ON NETX AT 2 SEN WITH MANY DOUBTERS ABOUND

WHEN NETX SHARE PRICE FINALLY CROSSES 8 SEN OR EVEN 15 SEN YOU MUST NOT BE SURPRISED THAT OTHER SIFU & GURU WILL STILL ASK YOU TO CHASE

BY THEN PLEASE BE VERY CAREFUL

BUT FOR NOW JUST BUY WHILE STILL SO CHEAP!!

BEST REGARDS

Calvin Tan Research

Singapore

Please buy or sell after doing your own due diligence

 

QUESTIONS TO ASK:

OF SO MANY COMPANIES ASIABIO DIRECTORS ARE IN CHARGE WHY THEY CHOSE TO BUY SO MUCH NETX SHARES SUDDENLY?

DID THEY SEE SOMETHING GOOD IN NETX?

WILL NETX BENEFITS FROM THE NFCP RM21.6 BILLIONS FIBERISATION THRUST?

Recent Posts